MIAMI – November 09, 2026 -- OpenEvidence will license clinical guidance from the American College of Physicians (ACP) and peer-reviewed content from Annals of Internal Medicine, adding the content to its AI clinical decision support platform for U.S. physicians.
ACP is the largest medical specialty organization in the United States. OpenEvidence describes itself as the most popular AI for doctors in the country.
ACP guidelines and journal content move into the point-of-care workflow
The licensed material covers ACP's clinical guidelines, guidance statements, practice points and best practice advice. It also covers Annals of Internal Medicine content, which includes original research, review articles, clinical guidelines and commentary on clinical practice, health care delivery, public health, policy, medical education, ethics and research methodology.
Physicians using OpenEvidence will be able to access these recommendations and peer-reviewed articles within the platform. The companies say this supports real-time clinical decisions.
Internal medicine is already OpenEvidence's largest specialty
Travis Zack, MD, PhD, OpenEvidence's Chief Medical Officer, said internal medicine is the largest specialty on the platform. In a single clinic session, he said, an internist might move from a heart failure regimen to a thyroid nodule to a drug interaction in a patient taking ten medications. He said the licensing deal means more answers will draw on evidence internists already trust, with citations shown for verification.
ACP's reach spans 163,000 members
ACP has 163,000 members, according to the announcement. ACP's own boilerplate separately cites 152,000 internal medicine physicians, related subspecialists and medical students, with members in more than 172 countries.
ACP President Jan K. Carney, MD, MPH, MACP, FRCP, said access to ACP guidance and Annals content where and when physicians need it can help them make more informed decisions and spend more time on patient care.
OpenEvidence is free to verified U.S. clinicians
OpenEvidence says more American physicians use its platform than all other AI platforms combined, citing independent studies. It says the majority of U.S. physicians use it daily on average. The platform is free for all verified U.S. clinicians. The companies did not disclose financial terms or a launch date for the integration.